rss
Br J Ophthalmol 2009;93:468-473 doi:10.1136/bjo.2008.141366
  • Clinical science
    • Original Article

Observational prospective study of the effectiveness in routine clinical practice of verteporfin photodynamic therapy in patients with neovascular age-related macular degeneration

  1. S Murjaneh1,
  2. M García-Fiñana2,
  3. S Mahmood1,
  4. P M Lenfestey1,
  5. S A Taylor1,
  6. I A Pearce1,
  7. M C Briggs1,
  8. H Heimann1,
  9. S P Harding1
  1. 1
    St Paul’s Eye Unit, Royal Liverpool University Hospital, Liverpool, UK
  2. 2
    Centre for Medical Statistics and Health Evaluation, University of Liverpool, Liverpool, UK
  1. Professor S P Harding, Consultant Ophthalmic Surgeon, St Paul’s Eye Unit, Royal Liverpool University Hospital, Prescot Street, Liverpool L7 8XP, UK; s.p.harding{at}liverpool.ac.uk
  • Accepted 28 August 2008
  • Published Online First 15 December 2008

Abstract

Aims: To investigate effectiveness in routine clinical practice of verteporfin photodynamic therapy (PDT) for neovascular age-related macular degeneration (nAMD).

Patients and methods: Patients commencing PDT for nAMD in a single UK centre entered a prospective observational 7-year study and were followed for 2 years. Best-corrected visual acuity (BCVA) and contrast sensitivity (CS) were measured at each visit by accredited technicians after full protocol refraction on standardised charts. Reasons for failure to complete the course of therapy were documented.

Results: 1008 patients entered the study between 1999 and 2006. 81% and 52% completed 12 and 24 months’ follow-up respectively (excluding administrative censoring). Results at 12 and 24 months respectively were: maintenance of BCVA 62%, 63%; drop in mean BCVA (letters) 10.1, 9.4; numbers of treatments 2.9, 3.5. The mean CS remained stable. No correlation of change in BCVA outcome between first and second treated eyes in 82 bilateral cases was detected. Loss to follow-up was significantly associated with age, CS and distance from the treating centre.

Conclusions: PDT delivered in clinical practice is at least as effective as that reported in randomised clinical trials and uses fewer treatments.

Footnotes

  • Competing interests: St Paul’s Eye Unit has received departmental commercial funding as a clinical centre in the TAP and VIP studies. SAT, IAP, MCB, HH and SPH have received support for travel and conference attendance.

  • Patient consent: Obtained.

This Article

  1. Abstract
  2. Full text
  3. PDF
  4. All Versions of this Article:
    1. bjo.2008.141366v1
    2. 93/4/468 most recent

Responses

  1. Submit a response
  2. No responses published

Social bookmarking

Register for free content


Free sample
 This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of BJO.
View free sample issue >>

Free archive
The full back archive is now available for BJO. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006, back to volume 1 issue 1.
Register to access the free archive >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.